

OVER-THE-COUNTER (OTC) DRUGS AND DIETARY SUPPLEMENTS: GLOBAL MARKETS



PHM050C
March 2017

Anand Gijare
Project Analyst

ISBN: 1-62296-451-9



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
info@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
GLOBAL OTC DRUG MARKETS BY LEADING THERAPEUTIC SEGMENTS, 2016 THROUGH 2021	8
<i>SUMMARY TABLE A GLOBAL THERAPEUTIC MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS, BY SEGMENT, THROUGH 2021 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE A GLOBAL THERAPEUTIC MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS, BY SEGMENT, 2015-2021 (\$ MILLIONS)</i>	9
GLOBAL DIETARY SUPPLEMENT MARKETS, 2016 THROUGH 2021	10
<i>SUMMARY TABLE B REGIONAL MARKETS FOR DIETARY SUPPLEMENTS, THROUGH 2021 (\$ MILLIONS)</i>	10
<i>SUMMARY FIGURE B REGIONAL MARKETS FOR DIETARY SUPPLEMENTS, 2015-2021 (\$ MILLIONS)</i>	10
CHAPTER 3 OVERVIEW	13
EVOLUTION OF OTC DRUGS	13
KEY GROWTH FACTORS FOR OTC DRUGS AND DIETARY SUPPLEMENT MARKETS	15
<i>FIGURE 1 KEY GROWTH FACTORS FOR OTC DRUGS AND DIETARY SUPPLEMENTS MARKET</i>	15
INDUSTRY DRIVERS FOR OTC DRUGS	16
PREVALENCE OF SELF-CARE	16
BURDEN ON PUBLIC HEALTH SYSTEM	17
RETAIN MARKET LEADERSHIP	18
RULES AND REGULATIONS FOR OTC DRUGS AND DIETARY SUPPLEMENTS	19
REGULATIONS FOR OTC DRUGS	20
REGULATIONS FOR DIETARY SUPPLEMENTS	21
MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS	22
WELL-DEVELOPED MARKETS	22
DEVELOPING MARKETS	23
UNDER-DEVELOPED MARKETS	25
CHAPTER 4 GLOBAL OTC DRUGS AND DIETARY SUPPLEMENT MARKETS	27
GLOBAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS 2016 THROUGH 2021	27
<i>TABLE 1 GLOBAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS, THROUGH 2021 (\$ MILLIONS)</i>	27

TOPIC	PAGE NO.
REGIONAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENT MARKETS 2016 THROUGH 2021	28
<i>TABLE 2 REGIONAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS, THROUGH 2021 (\$ MILLIONS)</i>	28
GLOBAL SALES FORECAST FOR OTC DRUGS AND DIETARY SUPPLEMENTS BY THERAPEUTIC CLASSIFICATION	29
<i>TABLE 3 GLOBAL MARKET FOR OTC DRUGS AND DIETARY SUPPLEMENTS, BY THERAPEUTIC CLASSIFICATION, THROUGH 2021 (\$ MILLIONS)</i>	29
GLOBAL OTC DRUGS AND DIETARY SUPPLEMENT MARKETS BY LOCATION OF SALES 2016 THROUGH 2021	30
<i>TABLE 4 OTC DRUGS REVENUE, BY LOCATION OF SALES, THROUGH 2021 (\$ MILLIONS)</i>	30
<i>TABLE 5 DIETARY SUPPLEMENTS REVENUE, BY LOCATION OF SALES, THROUGH 2021 (\$ MILLIONS)</i>	30
GLOBAL MARKET FORECAST FOR OTC DRUGS AND DIETARY SUPPLEMENTS BY SALES OUTLETS, THROUGH 2021	31
CHAPTER 5 OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN THE AMERICAS	34
OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN NORTH AMERICA 2016 THROUGH 2021	34
NORTH AMERICA OTC DRUGS MARKETS 2016 THROUGH 2021	34
<i>TABLE 6 NORTH AMERICA OTC DRUG MARKETS, THROUGH 2021 (\$ MILLIONS)</i>	34
NORTH AMERICA DIETARY SUPPLEMENT MARKETS 2016 THROUGH 2021	34
<i>TABLE 7 NORTH AMERICA DIETARY SUPPLEMENT MARKETS, THROUGH 2021 (\$ MILLIONS)</i>	34
NORTH AMERICA OTC DRUGS AND DIETARY SUPPLEMENTS MARKETS BY THERAPEUTIC CLASSIFICATION 2016 THROUGH 2021	35
<i>TABLE 8 NORTH AMERICA OTC DRUGS AND DIETARY SUPPLEMENTS MARKET, BY THERAPEUTIC CLASSIFICATION, THROUGH 2021 (\$ MILLIONS)</i>	35
OTC DRUGS AND DIETARY SUPPLEMENTS IN THE U.S.	35
VENDOR ECOSYSTEM FOR OTC DRUGS IN THE U.S.	36
MULTINATIONAL OTC DRUG MANUFACTURERS	36
STORE BRANDS	36
FMCG COMPANIES	37
REGULATIONS AND APPROVAL PROCESS: THE U.S.	37
Drugs Developed Under the OTC Drug Monograph Process	37
OTC Drug Review	38
OTC Monograph	38
OTC Drugs Developed Through the NDA Process	39
Updated List of Prescription to Over-the-Counter (OTC) Switches	39
<i>TABLE 9 UPDATED LIST OF RX-TO-OTC SWITCHES IN THE U.S. FROM 2001 TO 2016</i>	39
THE U.S. NONPRESCRIPTION SAFE-USE REGULATORY EXPANSION (NSURE) INITIATIVE	41
THE U.S. OTC DRUGS AND DIETARY SUPPLEMENT MARKET 2016-2021	43
<i>TABLE 10 THE U.S. OTC DRUG AND DIETARY SUPPLEMENTS MARKET, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)</i>	43
BRAZIL OTC DRUGS MARKET	44
BRAZIL OTC DRUGS AND DIETARY SUPPLEMENTS MARKET 2016 THROUGH 2021	45

TOPIC	PAGE NO.
<i>TABLE 11 BRAZIL OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)</i>	46
CHAPTER 6 THE OTC DRUG AND DIETARY SUPPLEMENT MARKETS IN EUROPE	48
BREXIT EFFECT ON THE OTC DRUG MARKET IN EUROPE	48
REGULATIONS AND APPROVAL PROCESS IN EUROPE	49
National Procedure	49
Decentralized Procedure	49
Mutual Recognition Procedure	49
Centralized Procedure	50
SMART REGULATION 2015: EUROPE AS A SINGLE MARKET	50
OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN EUROPE 2016 - 2021	51
EUROPEAN OTC DRUGS AND DIETARY SUPPLEMENT MARKETS 2016 - 2021	52
<i>TABLE 12 EUROPEAN OTC DRUG MARKETS, THROUGH 2021 (\$ MILLIONS)</i>	52
OTC DRUGS AND DIETARY SUPPLEMENT MARKETS: WESTERN EUROPE THROUGH 2021	53
<i>TABLE 13 EUROPEAN OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)</i>	53
THE U.K. OTC DRUG AND DIETARY SUPPLEMENTS MARKET	54
THE REGULATIONS AND APPROVAL PROCESS IN THE U.K.	54
Better Regulation of Over-the-Counter Drugs Initiative (BROMI) U.K.	56
POM TO P RECLASSIFICATIONS UP TO OCTOBER 2016	56
<i>TABLE 14 U.K. POM TO P RECLASSIFICATIONS UP TO OCTOBER 2016</i>	56
<i>TABLE 15 P TO GSL RECLASSIFICATIONS UP TO OCTOBER 2016</i>	58
POM TO P RECLASSIFICATIONS IN THE U.K. APPROVED FROM 2010 TO 2015	59
<i>TABLE 16 RECENT POM TO P RECLASSIFICATIONS AND NONPRESCRIPTION MARKETING AUTHORIZATIONS: U.K., 2010-2015</i>	59
<i>TABLE 17 RECENT P TO GSL RECLASSIFICATIONS AND NONPRESCRIPTION MARKETING AUTHORIZATIONS - U.K., 2011-2015</i>	59
U.K. OTC DRUGS AND DIETARY SUPPLEMENT MARKET 2016 THROUGH 2021	60
<i>TABLE 18 THE U.K. OTC DRUG AND DIETARY SUPPLEMENTS MARKET, BY THERAPEUTIC CLASSIFICATION, THROUGH 2021 (\$ MILLIONS)</i>	61
GERMAN OTC DRUG AND DIETARY SUPPLEMENTS MARKET	61
THE REGULATIONS AND APPROVAL PROCESS IN GERMANY	62
OTC DRUG SWITCHES IN GERMANY FROM 2005 TO 2016	63
<i>TABLE 19 OTC DRUG SWITCHES IN GERMANY FROM 2005 TO 2016</i>	63
GERMAN OTC DRUG AND DIETARY SUPPLEMENTS MARKET 2016 THROUGH 2021	63
<i>TABLE 20 GERMANY OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)</i>	64
FRANCE'S OTC DRUGS AND DIETARY SUPPLEMENTS MARKET 2016 THROUGH 2021	64
<i>TABLE 21 FRANCE OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)</i>	65
OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN CENTRAL AND EASTERN EUROPE	66
<i>TABLE 22 CCE OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)</i>	66

TOPIC	PAGE NO.
THE RUSSIAN OTC DRUG AND DIETARY SUPPLEMENTS MARKET 2016 THROUGH 2021	67
<i>TABLE 23 RUSSIAN OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)</i>	67
THE POLISH OTC DRUG AND DIETARY SUPPLEMENTS MARKET 2016 THROUGH 2021	68
<i>TABLE 24 POLISH OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)</i>	69
CHAPTER 7 OTC DRUGS AND DIETARY SUPPLEMENT MARKETS IN ASIA-PACIFIC	71
APAC OTC DRUGS AND DIETARY SUPPLEMENTS MARKETS 2016 THROUGH 2021	71
<i>TABLE 25 APAC OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)</i>	72
JAPAN'S OTC DRUGS MARKET	72
The Regulation and Approval Process in Japan	73
Reviews Conducted for OTC Drugs In Japan, by Fiscal Year	74
<i>TABLE 26 REVIEWS CONDUCTED FOR OTC DRUGS IN JAPAN, BY FISCAL YEAR, 2011-2015</i>	74
First Kind Pharmaceutical Newly Approved - Japan's OTC Pharmaceutical Sales System	74
<i>TABLE 27 UPDATED LIST OF OTC TO FIRST KIND PHARMACEUTICAL DRUGS IN JAPAN, NOV. 2007-MARCH 2016</i>	74
JAPAN'S OTC DRUGS AND DIETARY SUPPLEMENTS MARKET 2016 THROUGH 2021	77
<i>TABLE 28 JAPAN OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)</i>	77
CHINA OTC DRUG MARKETS 2016 THROUGH 2021	77
THE REGULATION AND APPROVAL PROCESS: CHINA	78
New Amendments in Regulating Drug Advertising in 2015	79
CHINA - OTC DRUGS AND DIETARY SUPPLEMENTS MARKET 2016 THROUGH 2021	79
<i>TABLE 29 CHINA OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)</i>	79
INDIA OTC DRUG MARKETS	80
INDIA: REGULATION AND APPROVAL PROCESSES	81
INDIA - OTC DRUGS AND DIETARY SUPPLEMENTS MARKET 2016 THROUGH 2021	81
<i>TABLE 30 INDIA OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)</i>	82
AUSTRALIA AND NEW ZEALAND'S OTC DRUGS AND DIETARY SUPPLEMENTS MARKET	82
Regulation and Approval Process: Australia	83
NEW ZEALAND	84
JOINT AUSTRALIAN AND NEW ZEALAND PHASED IMPLEMENTATION PLAN 2013	85
N2 Applications (Using OTC Monographs) Version1, September 2013	85
Level N3, N4 and N5 Applications	86
AUSTRALIA AND NEW ZEALAND: OTC DRUGS MARKET 2016 THROUGH 2021	86
<i>TABLE 31 AUSTRALIA AND NEW ZEALAND OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)</i>	86

TOPIC	PAGE NO.
CHAPTER 8 GLOBAL MARKET FORECAST FOR OTC DRUGS BY THERAPEUTIC CLASSIFICATION	88
OTC ANALGESICS/ANTIPYRETICS MARKETS 2021	88
ACETAMINOPHEN	88
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)	88
MARKET FORECASTS 2016 THROUGH 2021	90
<i>TABLE 32 GLOBAL MARKET FORECAST FOR OTC ANALGESICS AND ANTIPYRETICS, THROUGH 2021 (\$ MILLIONS)</i>	90
OTC ANTIHISTAMINE AND COUGH AND COLD DRUGS MARKETS 2021	91
ANTIHISTAMINES	91
COUGH AND COLD REMEDIES	92
Nasal Decongestants	92
Cough Remedies	92
GLOBAL MARKET FORECASTS THROUGH 2021	93
<i>TABLE 33 GLOBAL MARKET FORECAST FOR OTC ANTIHISTAMINE AND COUGH AND COLD, THROUGH 2021 (\$ MILLIONS)</i>	93
OTC GASTROINTESTINAL PRODUCTS MARKETS 2021	93
GASTROINTESTINAL DISORDER TREATMENTS	93
Antacids	94
H2 Blockers	94
Proton Pump Inhibitors (PPIs)	94
GLOBAL MARKET FORECAST FOR THROUGH 2021	95
<i>TABLE 34 GLOBAL MARKET FORECAST FOR OTC GASTROINTESTINAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	95
OTC DERMATOLOGICAL DRUGS MARKETS 2021	95
SKINCARE AND DERMATOLOGICAL DRUGS	96
Acne Treatments	96
Psoriasis	97
GLOBAL MARKET FORECAST THROUGH 2021	97
<i>TABLE 35 GLOBAL MARKET FORECAST FOR OTC DERMATOLOGICAL DRUGS, THROUGH 2021 (\$ MILLIONS)</i>	97
OTC ORAL MEDICAL CARE PRODUCTS MARKETS 2021	98
ORAL MEDICAL CARE	98
Oral Debriding Agents and Wound Cleansers	98
Treatments for Dental Carries	98
Treatments on Gum Diseases	98
Treatments for Cold Sores	99
GLOBAL MARKET FORECAST FOR THROUGH 2021	99
<i>TABLE 36 GLOBAL MARKET FORECAST FOR OTC ORAL MEDICAL CARE PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	99
GLOBAL MARKET FORECAST FOR OTC EYE CARE PRODUCTS	99
EYE CARE PRODUCTS	99
Treatments for Dry Eye	100
Ocular Allergy Symptoms	100
Ocular/Eye Vitamins	100
Eyelid Hygiene	100
Contact Lenses Solution	100
Dry Eye	101

TOPIC	PAGE NO.
GLOBAL MARKET FORECAST THROUGH 2021	101
<i>TABLE 37 GLOBAL MARKET FORECAST FOR OTC EYE CARE PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	101
OTC SMOKING CESSATION PRODUCTS MARKETS 2021	101
SMOKING CESSATION	102
Nicotine Gum	103
Nicotine Lozenges	103
Nicotine Patch	104
GLOBAL MARKET FORECAST FOR OTC SMOKING CESSATION PRODUCTS BY REGION THROUGH 2021	105
<i>TABLE 38 GLOBAL MARKET FORECAST FOR OTC SMOKING CESSATION PRODUCTS, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	105
OTC DIETARY SUPPLEMENTS (VMS) MARKETS 2021	106
EATING DISORDERS	106
TREATMENTS FOR VITAMINS AND MINERAL DEFICIENCY	106
VITAMINS AND MINERAL SUPPLEMENTS (VMS)	107
GLOBAL MARKET FORECAST THROUGH 2021	107
<i>TABLE 39 GLOBAL MARKET FORECAST FOR OTC DIETARY SUPPLEMENT PRODUCTS, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	107
CHAPTER 9 OTC DRUG INDUSTRY ROADMAP	109
THE PRACTICE OF BUYING OTC DRUGS	109
ROLE OF PHARMACY IN OTC DRUGS	109
REGULATORY INFLUENCE ON OTC DRUG MARKET	109
KEY STRATEGIC INITIATIVES FOR MARKET PENETRATION AND EXPANSION	110
ACQUISITION OF MARKETING AUTHORIZATION: KEY MARKET PENETRATION AND EXPANSION STRATEGY	110
EXPANSIONS, PARTNERSHIPS AND JOINT VENTURES	111
THIRD-PARTY CONTRACTING	112
DRIVERS OF AND BARRIERS TO THE OTC DRUG INDUSTRY	112
RECENT DRIVERS FOR THE OTC DRUGS AND DIETARY SUPPLEMENT MARKET	112
STRENGTHS, WEAKNESSES, OPPORTUNITIES AND THREATS (SWOT) ANALYSIS OF THE OTC DRUG AND DIETARY SUPPLEMENT INDUSTRY	113
<i>TABLE 40 SWOT ANALYSIS OF THE OTC DRUG AND DIETARY SUPPLEMENT INDUSTRY</i>	113
CHAPTER 10 COMPANY PROFILES	116
ALACER CORP.	116
ALCON INC.	116
ALFRESA PHARMA CORPORATION	116
ALKALON A/S	116
ALLIANCE HEALTHCARE	117
ALLIANCE HEALTHCARE DEUTSCHLAND	117
ALLIANCE HEALTHCARE FRANCE	117
ALLERGAN, PLC.	117
ALTICOR	118
NUTRILITE	118

TOPIC	PAGE NO.
ARKOPHARMA PHARMACEUTICAL LABORATORIES (LABORATOIRES PHARMACEUTIQUES)	118
ASPEN HOLDINGS	118
ASPEN PHARMACARE AUSTRALIA PTY. LTD.	119
BAUSCH & LOMB	119
BAYER HEALTHCARE AG	119
BOEHRINGER INGELHEIM GMBH	120
CARMA LABORATORIES, INC.	120
CHATTEM INC.	120
CILAG AG	121
COLGATE-PALMOLIVE COMPANY	121
DAIICHI SANKYO CO., LTD.	121
DERMA SCIENCES	122
EYESCIENCE LABS	122
FERTIN PHARMA A/S	122
GABA GMBH, PC	122
GABA SCHWEIZ	123
GALDERMA S.A.	123
GEMINI PHARMACEUTICALS, INC.	123
GENOMMA LAB INTERNATIONAL	123
GENOMMA LAB USA	124
GLAXOSMITHKLINE PLC	124
HISAMITSU PHARMACEUTICAL CO., INC.	124
JOHNSON & JOHNSON	125
KOWA COMPANY, LTD.	125
LAKE CONSUMER PRODUCTS, INC.	125
MANX HEALTHCARE LIMITED	126
MCM KLOSTERFRAU VERTRIEBS GMBH (KLOSTERFRAU HEALTHCARE GROUP)	126
MEDA AB	126
MELALEUCA, INC.	126
MERCK CORPORATE HEADQUARTERS	127
MERCK CANADA	127
MERCK CHINA	127
MERZ PHARMA	127
MOCHIDA PHARMACEUTICAL CO., LTD.	128
NEPENTES SA/NEPENTES PHARMA SP. Z O.O.	128
NEUTROGENA CORP.	128
NORTHEAST PHARMACEUTICAL GROUP CO. LTD	128
NOVARTIS INTERNATIONAL AG	129
NOW FOODS	129
PERRIGO PLC	129
PFIZER INC.	130
PGT HEALTHCARE (DIVISION OF PROCTER & GAMBLE)	130
PHARMAVITE LLC	130
PIERRE FABRE PHARMACEUTICALS INC.	130
PIRAMAL HEALTHCARE LTD	131
PRESTIGE BRANDS HOLDINGS, INC.	131
RECKITT BENCKISER PLC.	132

TOPIC	PAGE NO.
RECKITT BENCKISER (NORTH AMERICA) INC.	132
RECORDATI PHARMA GMBH	132
REVOLYMER (U.K.) LTD	132
SAGE PRODUCTS LLC	133
SANOFI	133
SATO PHARMACEUTICAL CO., LTD.	133
SHAKLEE CORPORATION	134
STADA ARZNEIMITTEL AG	134
SWISSE WELLNESS PTY LTD.	134
TAISHO PHARMACEUTICAL HOLDINGS	135
TAKEDA PHARMACEUTICALS LTD.	135
TISSO NATURPRODUKTE GMBH	135
WELLSPRING PHARMACEUTICAL CORPORATION	136
ZEAVISION, LLC	136
CHAPTER 11 APPENDIX I	138
MARKET DEFINITIONS	138
OTC DRUGS	138
DIETARY SUPPLEMENTS (VMS)	139
COMMON ADMINISTRATION METHODS FOR OTC DRUGS	140
TOPICAL ADMINISTRATION	140
Lotion	140
Cream	140
Ointment	141
Gel	141
Transdermal Patch	141
ORAL ADMINISTRATION	141
Tablets	141
Capsules	142
Medicinal Syrups	142
Medicated Chewing Gums	142
CHAPTER 12 APPENDIX II	144
SMOKING CESSATION INITIATIVES	144
HIGH RATE OF SMOKERS QUITTING IN DEVELOPED COUNTRIES	144
DECREASE IN SMOKING RATES AT SATURATION POINT IN DEVELOPED MARKETS	144
SMOKING RATES ARE INCREASING IN DEVELOPING MARKETS	144
STRATEGIC INITIATIVES TO INCREASE SMOKING CESSATION IN DEVELOPING COUNTRIES	145
DEVELOPING AND POOR COUNTRIES SIGN WHO FCTC TREATY	145
WHO FCTC PROGRESS REPORT 2012	145
<i>TABLE 41 ARTICLES REPORTED TO HAVE HIGHEST IMPLEMENTATION RATES IN 2012 WHO FCTC PROGRESS REPORT (%)</i>	146
<i>TABLE 42 ARTICLES REPORTED MODERATE IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT (%)</i>	146
<i>TABLE 43 ARTICLES REPORTED LOWEST IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT (%)</i>	147

TOPIC	PAGE NO.
<i>FIGURE 2 GLOBAL IMPLEMENTATION OF ARTICLES OF 2012 WHO FCTC PROGRESS REPORT (%)</i>	147
<i>TABLE 44 GLOBAL IMPLEMENTATION OF FCTC ARTICLES: 2012 REPORT</i>	148
Implementation of Article 14 in 2012	150
<i>TABLE 45 GLOBAL IMPLEMENTATION OF ARTICLE 14 OF FCTC</i>	150
Political and Legal Interventions Influence Markets	151
<i>TABLE 46 INITIATIVES IMPLEMENTED BY PARTIES TO FCTC TREATY IN 2012 (%)</i>	152
Socioeconomic Factors of Smoking	153
<i>TABLE 47 PROJECTED GLOBAL CAUSE OF DEATH, BY DISEASE (%)</i>	155
<i>TABLE 48 PUBLIC HEALTH BURDEN DUE TO SMOKING-RELATED DISEASES (\$ BILLIONS)</i>	155
Technological Developments Concerning Smoking	155
<i>FIGURE 3 ONGOING STUDIES, BY REGION (NO. OF STUDIES)</i>	156
CHAPTER 13 APPENDIX III	159
OTC MARKETS 2013 THROUGH 2018	159
<i>TABLE 49 GLOBAL MARKET FOR OTC DRUGS AND DIETARY SUPPLEMENTS, THROUGH 2018 (\$ MILLIONS)</i>	159
<i>FIGURE 4 GLOBAL MARKET FOR OTC DRUGS AND DIETARY SUPPLEMENTS, 2011-2018 (\$ MILLIONS)</i>	159
HIGHLIGHTS OF THE YEAR 2012	160
TRENDS IN OTC DRUGS AND DIETARY SUPPLEMENTS THROUGH 2018	161
FORECAST TRENDS IN OTC DRUGS BY THERAPEUTIC CLASS THROUGH 2018	162

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE A GLOBAL THERAPEUTIC MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS, BY SEGMENT, THROUGH 2021 (\$ MILLIONS)	8
SUMMARY TABLE B REGIONAL MARKETS FOR DIETARY SUPPLEMENTS, THROUGH 2021 (\$ MILLIONS)	10
TABLE 1 GLOBAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS, THROUGH 2021 (\$ MILLIONS)	27
TABLE 2 REGIONAL MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS, THROUGH 2021 (\$ MILLIONS)	28
TABLE 3 GLOBAL MARKET FOR OTC DRUGS AND DIETARY SUPPLEMENTS, BY THERAPEUTIC CLASSIFICATION, THROUGH 2021 (\$ MILLIONS)	29
TABLE 4 OTC DRUGS REVENUE, BY LOCATION OF SALES, THROUGH 2021 (\$ MILLIONS)	30
TABLE 5 DIETARY SUPPLEMENTS REVENUE, BY LOCATION OF SALES, THROUGH 2021 (\$ MILLIONS)	30
TABLE 6 NORTH AMERICA OTC DRUG MARKETS, THROUGH 2021 (\$ MILLIONS)	34
TABLE 7 NORTH AMERICA DIETARY SUPPLEMENT MARKETS, THROUGH 2021 (\$ MILLIONS)	34
TABLE 8 NORTH AMERICA OTC DRUGS AND DIETARY SUPPLEMENTS MARKET, BY THERAPEUTIC CLASSIFICATION, THROUGH 2021 (\$ MILLIONS)	35
TABLE 9 UPDATED LIST OF RX-TO-OTC SWITCHES IN THE U.S. FROM 2001 TO 2016	39
TABLE 10 THE U.S. OTC DRUG AND DIETARY SUPPLEMENTS MARKET, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)	43
TABLE 11 BRAZIL OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)	46
TABLE 12 EUROPEAN OTC DRUG MARKETS, THROUGH 2021 (\$ MILLIONS)	52
TABLE 13 EUROPEAN OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)	53
TABLE 14 U.K. POM TO P RECLASSIFICATIONS UP TO OCTOBER 2016	56
TABLE 15 P TO GSL RECLASSIFICATIONS UP TO OCTOBER 2016	58
TABLE 16 RECENT POM TO P RECLASSIFICATIONS AND NONPRESCRIPTION MARKETING AUTHORIZATIONS: U.K., 2010-2015	59
TABLE 17 RECENT P TO GSL RECLASSIFICATIONS AND NONPRESCRIPTION MARKETING AUTHORIZATIONS - U.K., 2011-2015	59
TABLE 18 THE U.K. OTC DRUG AND DIETARY SUPPLEMENTS MARKET, BY THERAPEUTIC CLASSIFICATION, THROUGH 2021 (\$ MILLIONS)	61
TABLE 19 OTC DRUG SWITCHES IN GERMANY FROM 2005 TO 2016	63
TABLE 20 GERMANY OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)	64
TABLE 21 FRANCE OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)	65
TABLE 22 CCE OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)	66
TABLE 23 RUSSIAN OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)	67
TABLE 24 POLISH OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)	69
TABLE 25 APAC OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)	72
TABLE 26 REVIEWS CONDUCTED FOR OTC DRUGS IN JAPAN, BY FISCAL YEAR, 2011-2015	74

TABLE HEADING	PAGE NO.
TABLE 27 UPDATED LIST OF OTC TO FIRST KIND PHARMACEUTICAL DRUGS IN JAPAN, NOV. 2007-MARCH 2016	74
TABLE 28 JAPAN OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)	77
TABLE 29 CHINA OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)	79
TABLE 30 INDIA OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)	82
TABLE 31 AUSTRALIA AND NEW ZEALAND OTC DRUG AND DIETARY SUPPLEMENTS MARKETS, BY THERAPEUTIC CLASSIFICATIONS, THROUGH 2021 (\$ MILLIONS)	86
TABLE 32 GLOBAL MARKET FORECAST FOR OTC ANALGESICS AND ANTIPYRETICS, THROUGH 2021 (\$ MILLIONS)	90
TABLE 33 GLOBAL MARKET FORECAST FOR OTC ANTIHISTAMINE AND COUGH AND COLD, THROUGH 2021 (\$ MILLIONS)	93
TABLE 34 GLOBAL MARKET FORECAST FOR OTC GASTROINTESTINAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	95
TABLE 35 GLOBAL MARKET FORECAST FOR OTC DERMATOLOGICAL DRUGS, THROUGH 2021 (\$ MILLIONS)	97
TABLE 36 GLOBAL MARKET FORECAST FOR OTC ORAL MEDICAL CARE PRODUCTS, THROUGH 2021 (\$ MILLIONS)	99
TABLE 37 GLOBAL MARKET FORECAST FOR OTC EYE CARE PRODUCTS, THROUGH 2021 (\$ MILLIONS)	101
TABLE 38 GLOBAL MARKET FORECAST FOR OTC SMOKING CESSATION PRODUCTS, BY REGION, THROUGH 2021 (\$ MILLIONS)	105
TABLE 39 GLOBAL MARKET FORECAST FOR OTC DIETARY SUPPLEMENT PRODUCTS, BY REGION, THROUGH 2021 (\$ MILLIONS)	107
TABLE 40 SWOT ANALYSIS OF THE OTC DRUG AND DIETARY SUPPLEMENT INDUSTRY	113
TABLE 41 ARTICLES REPORTED TO HAVE HIGHEST IMPLEMENTATION RATES IN 2012 WHO FCTC PROGRESS REPORT (%)	146
TABLE 42 ARTICLES REPORTED MODERATE IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT (%)	146
TABLE 43 ARTICLES REPORTED LOWEST IMPLEMENTATION RATES: 2012 WHO FCTC PROGRESS REPORT (%)	147
TABLE 44 GLOBAL IMPLEMENTATION OF FCTC ARTICLES: 2012 REPORT	148
TABLE 45 GLOBAL IMPLEMENTATION OF ARTICLE 14 OF FCTC	150
TABLE 46 INITIATIVES IMPLEMENTED BY PARTIES TO FCTC TREATY IN 2012 (%)	152
TABLE 47 PROJECTED GLOBAL CAUSE OF DEATH, BY DISEASE (%)	155
TABLE 48 PUBLIC HEALTH BURDEN DUE TO SMOKING-RELATED DISEASES (\$ BILLIONS)	155
TABLE 49 GLOBAL MARKET FOR OTC DRUGS AND DIETARY SUPPLEMENTS, THROUGH 2018 (\$ MILLIONS)	159

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE A GLOBAL THERAPEUTIC MARKETS FOR OTC DRUGS AND DIETARY SUPPLEMENTS, BY SEGMENT, 2015-2021 (\$ MILLIONS)	9
SUMMARY FIGURE B REGIONAL MARKETS FOR DIETARY SUPPLEMENTS, 2015-2021 (\$ MILLIONS)	10
FIGURE 1 KEY GROWTH FACTORS FOR OTC DRUGS AND DIETARY SUPPLEMENTS MARKET	15
FIGURE 2 GLOBAL IMPLEMENTATION OF ARTICLES OF 2012 WHO FCTC PROGRESS REPORT (%)	147
FIGURE 3 ONGOING STUDIES, BY REGION (NO. OF STUDIES)	156
FIGURE 4 GLOBAL MARKET FOR OTC DRUGS AND DIETARY SUPPLEMENTS, 2011-2018 (\$ MILLIONS)	159